PROK

MKT CAP:$567M

ProKidney Corp.

Market Cap

$567M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.00-$0.23 (-10.31%)

Apr 23, 2026

Company Details

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well ...

CEO

Bruce Culleton

IPO Date

Jun 30, 2021

Website

www.prokidney.com

Key Metrics TTM

Revenue

$217.0K

— YoY

Net Income

-$118M

EPS (Diluted)

-$0.73

Free Cash Flow

-$134M

Revenue / Share

$0.00

Gross Margin

-544.2%

Operating Margin

-74336.9%

Net Margin

-54384.3%

FCF Margin

-61653.5%

P/S

2615.0x

P/E

—

Earnings Reports

Q4 2025

May 11, 2026

PENDING

FY 2025

Mar 18, 2026

$893.0KEPS -$0.51

Q3 2025

Nov 10, 2025

$217.0KEPS -$0.12

Q3 2022

Nov 14, 2022

$0EPS -$0.13

Q2 2022

Aug 11, 2022

$0EPS -$0.36

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$0	$0	-$8M
Q1 21	$0	$0	-$12M
Q2 21	$0	$0	-$13M
Q3 21	$0	$0	-$17M
Q4 21	$0	$0	-$14M
Q1 22	$0	$0	-$66M
Q2 22	$0	$0	-$21M
Q3 22	$0	$0	-$36M
Q3 25	$217.0K	-$1M	-$39M

Valuation

Quarter	P/S	P/E
Q4 20	—	—
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	—	—
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q3 25	3390.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	-$8M	-$10M
Q1 21	-$7M	-$9M
Q2 21	-$12M	-$14M
Q3 21	-$37M	-$42M
Q4 21	-$13M	-$14M
Q1 22	-$15M	-$16M
Q2 22	-$23M	-$23M
Q3 22	-$61M	-$62M
Q3 25	-$27M	-$32M

Capital Expenditures

Quarter	CapEx
Q4 20	$3M
Q1 21	$1M
Q2 21	$2M
Q3 21	$5M
Q4 21	$540.0K
Q1 22	$839.0K
Q2 22	$386.0K
Q3 22	$2M
Q3 25	$5M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+75.6%
Q1 22	—	+472.8%
Q2 22	—	+63.1%
Q3 22	—	+108.3%
Q3 25	—	+182.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$184.0K	—
Q1 21	$175.0K	—
Q2 21	$175.0K	—
Q3 21	$0	—
Q4 21	$0	—
Q1 22	$53M	—
Q2 22	$8M	—
Q3 22	$0	—
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 20	$6M	$1M	$314.0K	—
Q1 21	$10M	$2M	—	—
Q2 21	$11M	$2M	—	—
Q3 21	$15M	$2M	—	—
Q4 21	$11M	$3M	—	—
Q1 22	$28M	$38M	—	—
Q2 22	$12M	$9M	—	—
Q3 22	$21M	$14M	—	—
Q3 25	$27M	—	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$30M	$0	$30M
Q2 22	$22M	$0	$22M
Q3 22	$506M	$0	$506M
Q4 22	$490M	$0	$490M
Q1 23	$272M	$192M	$464M
Q2 23	$244M	$203M	$446M
Q3 23	$191M	$205M	$396M
Q4 23	$61M	$302M	$363M
Q1 24	$84M	$245M	$329M
Q2 24	$215M	$217M	$432M
Q3 24	$108M	$299M	$407M
Q4 24	$99M	$259M	$358M
Q1 25	$98M	$231M	$328M
Q2 25	$85M	$210M	$295M
Q3 25	$95M	$176M	$272M
Q4 25	$109M	$161M	$270M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	115M	—	—
Q1 21	32M	-72.0%	—
Q2 21	32M	-0.9%	—
Q3 21	32M	-0.2%	—
Q4 21	32M	0.0%	-72.3%
Q1 22	32M	0.0%	-1.2%
Q2 22	62M	+93.0%	+92.5%
Q3 22	62M	0.0%	+93.0%
Q3 25	135M	+119.4%	+323.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	—	—
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	$0	3
Q1 22	$0	3
Q2 22	$0	3
Q3 22	$0	3
Q3 25	$1.1K	204

Revenue / Employee